Ross Products sales
This article was originally published in The Tan Sheet
Executive Summary
Abbott Labs' U.S. nutritional sales fall 1.9% to $579 mil. in Q1, driven by double-digit decline in pediatric nutritionals. Similac infant formula maker says pediatric sales "continued to be impacted by heavy competitive spending." Ross has increased promotional spending, which "is yielding positive results, and we're beginning to see the results of a turnaround in our non-WIC share, which has been under pressure in recent quarters," Divisional VP-Investor Relations John Thomas tells analysts during April 9 call. Launch of DHA/ARA-fortified Similac Advance, other marketing actions expected to drive second-half growth. Abbott's Q1 consolidated sales were $4.19 bil., up 17.7% from year-ago quarter, with net earnings of $854.3 mil., up 16.2% excluding one-time charges in 2001...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.